James C. Yao

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

R. Salazar, R. Riechelmann, E. Van Cutsem, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

E. Baudin, L. Kvols, P. Rougier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.

E. Van Cutsem, T. Hobday, C. Lombard-Bohas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.